Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Lenacapavir blocks HIV from entering and reproducing in human cells, providing long-term protection in a one-time dose. This ...

Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...

They added: “Yearly dosing of lenacapavir has the potential to further ... “PrEP as a daily pill has been a game-changer in our HIV response, the prospect of ‘safe’ annual injectable ...